- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This early-stage study is looking for a new treatment for advanced cancers that have a specific genetic change called a SMARCA4 mutation. The treatment is a tablet called PRT7732, and the study will check if it's safe and how it works in the body.
Germany · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Safety and Efficacy Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study looks at a new drug, PRT3789, with an existing cancer treatment, Pembrolizumab, for advanced solid tumours like lung cancer. It checks how safe and effective this combination is for people whose cancer has a specific change called a SMARCA4 mutation.
Spain · Germany · France